Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [1] Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
    Furman, Richard R.
    Wierda, William G.
    Schuh, Anna
    Patten, Piers Em
    Chaves, Jorge M.
    Brown, Jennifer R.
    Munir, Talha
    Martin, Peter
    Awan, Farrukh T.
    Stephens, Deborah M.
    Ghia, Paolo
    Barrientos, Jacqueline C.
    Patel, Krish
    Woyach, Jennifer A.
    Butturini, Anna
    de Borja, Marianne
    Wang, Min Hui
    O'Brien, Susan
    Byrd, John C.
    BLOOD, 2022, 140 : 9873 - 9875
  • [2] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
    Furman, Richard R.
    Wierda, William G.
    Schuh, Anna
    Devereux, Stephen
    Chaves, Jorge M.
    Brown, Jennifer R.
    Hillmen, Peter
    Martin, Peter
    Awan, Farrukh T.
    Stephens, Deborah M.
    Ghia, Paolo
    Barrientos, Jacqueline C.
    Pagel, John M.
    Woyach, Jennifer
    Burke, Kathleen
    Covey, Todd
    Gulrajani, Michael
    Hamdy, Ahmed
    Izumi, Raquel
    Frigault, Melanie M.
    Patel, Priti
    Rothbaum, Wayne
    Wang, Min Hui
    O'Brien, Susan M.
    Byrd, John C.
    BLOOD, 2019, 134
  • [3] Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up
    Byrd, John C.
    Woyach, Jennifer A.
    Furman, Richard R.
    Martin, Peter
    O'Brien, Susan
    Brown, Jennifer R.
    Stephens, Deborah M.
    Barrientos, Jacqueline C.
    Patten, Piers Em
    Munir, Talha
    Patel, Krish
    Butturini, Anna
    de Borja, Marianne
    Wang, Min Hui
    Jain, Nitin
    Wierda, William G.
    BLOOD, 2022, 140 : 9865 - 9867
  • [4] Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
    Byrd, John C.
    Wierda, William G.
    Schuh, Anna
    Devereux, Stephen
    Chaves, Jorge M.
    Brown, Jennifer R.
    Hillmen, Peter
    Martin, Peter
    Awan, Farrukh T.
    Stephens, Deborah M.
    Ghia, Paolo
    Barrientos, Jacqueline
    Pagel, John M.
    Woyach, Jennifer A.
    Burke, Kathleen
    Covey, Todd
    Gulrajani, Michael
    Hamdy, Ahmed
    Izumi, Raquel
    Frigault, Melanie M.
    Patel, Priti
    Rothbaum, Wayne
    Wang, Min Hui
    O'Brien, Susan
    Furman, Richard R.
    BLOOD, 2020, 135 (15) : 1204 - 1213
  • [5] Acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at ∼4 years of follow-up
    Welslau, M.
    Jurczak, W.
    Pluta, A.
    Wach, M.
    Lysak, D.
    Simkovic, M.
    Kriachok, I
    Illes, A.
    De la Serna, J.
    Dolan, S.
    Campbell, P.
    Musuraca, G.
    Jacob, A.
    Avery, E. J.
    Hoon, Lee J.
    Usenko, G.
    Wang, M. H.
    Yu, T.
    Ghia, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 118 - 119
  • [6] Acalabrutinib vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Results at ∼4 Years of Follow-up
    Welslau, Manfred
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Simkovic, Martin
    Kryachok, Irina
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric
    Lee, Jae Hoon
    Usenko, Ganna
    Wang, Min Hui
    Yu, Ting
    Ghia, Paolo
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 170 - 170
  • [7] Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From the Phase 1/2 ACE-CL-001 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 14 - 16
  • [8] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study
    Byrd, John C.
    Wierda, William G.
    Schuh, Anna
    Devereux, Stephen
    Chaves, Jorge M.
    Brown, Jennifer R.
    Hillmen, Peter
    Martin, Peter
    Awan, Farrukh T.
    Stephens, Deborah M.
    Ghia, Paolo
    Barrientos, Jacqueline C.
    Pagel, John M.
    Woyach, Jennifer A.
    Charuworn, Prista
    Hamdy, Ahmed
    Izumi, Raquel
    Patel, Priti
    Rothbaum, Wayne M.
    Wang, Min Hui
    Furman, Richard R.
    BLOOD, 2017, 130
  • [9] Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
    Wendtner, Clemens-Martin
    Hillmen, Peter
    Mahadevan, Daruka
    Buehler, Andreas
    Uharek, Lutz
    Coutre, Steven
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Furman, Richard R.
    Kimby, Eva
    Gribben, John G.
    Gobbi, Marco
    Dreisbach, Luke
    Hurd, David D.
    Sekeres, Mikkael A.
    Ferrajoli, Alessandra
    Shah, Sheetal
    Zhang, Jennie
    Moutouh-de Parseval, Laure
    Hallek, Michael
    Heerema, Nyla A.
    Stilgenbauer, Stephan
    Chanan-Khan, Asher A.
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 417 - 423
  • [10] Acalabrutinib with obinutuzumab in treatmentnaive and relapsed/refractory chronic lymphocytic leukemia: 3-year follow-up
    Woyach, Jennifer
    Rogers, Kerry
    Bhat, Seema
    Blachly, James
    Jianfar, Mojgan
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Munugalavadla, Veerendra
    Quah, Cheng
    Wang, Min Hui
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2020, 61 : 17 - 18
12345